Discover Oncology (Feb 2024)

Research progress of Paris polyphylla in the treatment of digestive tract cancers

  • Jia Wang,
  • Bao-yi Ni,
  • Jing Wang,
  • Lei Han,
  • Xin Ni,
  • Xin-miao Wang,
  • Lu-chang Cao,
  • Qian-hui Sun,
  • Xin-pu Han,
  • Hu-jun Cui

DOI
https://doi.org/10.1007/s12672-024-00882-9
Journal volume & issue
Vol. 15, no. 1
pp. 1 – 18

Abstract

Read online

Abstract Cancer has become one of the most important causes of human death. In particular, the 5 year survival rate of patients with digestive tract cancer is low. Although chemotherapy drugs have a certain efficacy, they are highly toxic and prone to chemotherapy resistance. With the advancement of antitumor research, many natural drugs have gradually entered basic clinical research. They have low toxicity, few adverse reactions, and play an important synergistic role in the combined targeted therapy of radiotherapy and chemotherapy. A large number of studies have shown that the active components of Paris polyphylla (PPA), a common natural medicinal plant, can play an antitumor role in a variety of digestive tract cancers. In this paper, the main components of PPA such as polyphyllin, C21 steroids, sterols, and flavonoids, amongst others, are introduced, and the mechanisms of action and research progress of PPA and its active components in the treatment of various digestive tract cancers are reviewed and summarized. The main components of PPA have been thoroughly explored to provide more detailed references and innovative ideas for the further development and utilization of similar natural antitumor drugs.

Keywords